Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) maintains this comprehensive news hub for investors tracking developments in its clinical-stage cancer therapeutics. Our curated collection features official press releases, regulatory filings, and material event announcements related to the company’s protein phosphatase inhibitor pipeline.
This resource enables stakeholders to monitor critical updates including clinical trial progress for lead compound LB-100, financial disclosures, and strategic collaborations. All content is sourced directly from company communications and SEC filings to ensure reliability.
Key categories include Phase 1/2 trial results, intellectual property milestones, executive leadership changes, and quarterly earnings reports. Bookmark this page for timely access to investment-relevant developments in Lixte’s novel approach to enhancing chemotherapy and radiation efficacy through targeted phosphatase inhibition.
On June 2, 2021, Lixte Biotechnology Holdings announced the enrollment of the first patient in a Phase 1b clinical trial for LB-100, a PP2A inhibitor, in combination with chemotherapy for extensive stage small cell lung cancer (ED-SCLC). The trial, conducted at City of Hope, aims to assess the therapeutic benefit of LB-100 alongside carboplatin, etoposide, and atezolizumab. Preclinical data suggests that LB-100 enhances chemotherapy effectiveness in animal models. Approximately 30,000 new cases of small cell lung cancer are diagnosed annually in the U.S., highlighting the urgent need for effective treatments.
Lixte Biotechnology Holdings, Inc. has appointed Regina Brown, CPA, as an independent director and audit committee chair. Her extensive experience in public accounting, compliance, and taxation is seen as a valuable asset as the company expands. Brown has over 30 years of experience working with a diverse clientele, including large corporations and those with international operations. This appointment is expected to enhance Lixte's governance and oversight.
Lixte Biotechnology Holdings (Nasdaq: LIXT) announced participation in the Sidoti & Company LLC Virtual Microcap Conference on May 19-20, 2021. CEO John S. Kovach will present on May 20 at 12:15 p.m. ET, discussing the lead drug candidate LB-100, which enhances the efficacy of various anticancer treatments. Lixte's pipeline includes studies for four aggressive cancers, targeting a market exceeding $5 billion. The company aims to leverage its unique IP and lack of clinical competition for LB-100 to capture significant market share.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced participation in the virtual Benzinga Global Small Cap Conference on May 13-14, 2021. CEO John S. Kovach highlighted the potential of their lead drug candidate, LB-100, which targets aggressive cancers like myelodysplastic syndromes and glioblastoma. With a market exceeding $5 billion, Lixte aims to improve cancer treatment through its novel approach, having demonstrated positive preclinical results. The company's pipeline includes three clinical studies and one pharmacology study focused on LB-100.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced on April 13, 2021, the appointment of Gil N Schwartzberg to its Board of Directors following the resignation of Winson Ho. Dr. John S. Kovach, CEO, expressed confidence in Schwartzberg's contributions, noting his experience in guiding the company since its inception. Schwartzberg, former Chairman and CEO of the City of Hope National Medical Center, brings extensive expertise in cancer treatment and research. Lixte continues its focus on developing innovative cancer therapies, notably its lead compound, LB-100.
Lixte Biotechnology Holdings presents promising data on its lead drug candidate, LB-100, which has shown to enhance anti-tumor activity in over 40 preclinical studies without increasing toxicity. The company will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, with CEO John S. Kovach discussing ongoing studies and clinical trials focused on cancers such as myelodysplastic syndrome and glioblastoma. Notably, LB-100 is a first-in-class agent with no known competitors currently in clinical trials.
Lixte Biotechnology Holdings, a clinical-stage drug discovery company, will participate in the 33rd Annual Roth Conference from March 15-17, 2021. CEO John S. Kovach will present their lead compound, LB-100, a first-in-class protein phosphatase inhibitor aimed at enhancing cancer treatments. Currently, LB-100 is being tested in various phases for several cancers, including Myelodysplastic Syndromes and Advanced Soft Tissue Sarcoma. Notably, LB-100 demonstrates potential without increasing toxicity, and there are currently no direct competitors in the market.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed a Registered Direct Offering of $4.19 million in common stock, issuing 1,133,102 shares at $3.70 each. This offering was facilitated by WestPark Capital, which acted as Co-Placement Agent. The shares were issued under a previously filed shelf registration statement with the SEC. This funding aims to bolster Lixte’s clinical-stage drug development focused on cancer treatment and other serious diseases, indicating potential for growth in their innovative therapeutic pipeline.
WallachBeth Capital has successfully completed a $4.19 million Registered Direct Offering for Lixte Biotechnology Holdings (LIXT). A total of 1,133,102 shares of common stock were sold at $3.70 per share. The net proceeds will support working capital and further development of the lead clinical compound LB-100.
The offering was made under a previously filed shelf registration statement. The company is focused on innovative cancer treatment solutions, with LB-100 currently undergoing clinical trials.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced the completion of a registered direct offering, raising approximately $4.19 million through the sale of 1,133,102 shares of common stock at $3.70 per share. The funds will be allocated for working capital and further development of its lead clinical compound, LB-100. WestPark Capital, Inc. and WallachBeth Capital, LLC served as co-placement agents for this transaction.
